For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Nektar Therapeutics (NASDAQ: NKTR) closed at $1.11 down -8.26% from its previous closing price of $1.21. In other words, the price has decreased by -$8.26 from its previous closing price. On the day, 1.13 million shares were traded. NKTR stock price reached its highest trading level at $1.21 during the session, while it also had its lowest trading level at $1.11.
Ratios:
For a deeper understanding of Nektar Therapeutics’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.90 and its Current Ratio is at 5.15. In the meantime, Its Debt-to-Equity ratio is 2.76 whereas as Long-Term Debt/Eq ratio is at 2.49.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Rodman & Renshaw on June 28, 2024, initiated with a Buy rating and assigned the stock a target price of $2.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 14 ’24 when CHESS ROBERT sold 19,500 shares for $1.20 per share. The transaction valued at 23,400 led to the insider holds 255,273 shares of the business.
ROBIN HOWARD W sold 16,650 shares of NKTR for $29,138 on May 17 ’24. The President & CEO now owns 863,239 shares after completing the transaction at $1.75 per share. On May 17 ’24, another insider, Zalevsky Jonathan, who serves as the Chief R&D Officer of the company, sold 7,355 shares for $1.75 each. As a result, the insider received 12,871 and left with 257,670 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NKTR now has a Market Capitalization of 204262208 and an Enterprise Value of 152699216. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.19 while its Price-to-Book (P/B) ratio in mrq is 2.56. Its current Enterprise Value per Revenue stands at 1.639 whereas that against EBITDA is -1.187.
Stock Price History:
Over the past 52 weeks, NKTR has reached a high of $1.93, while it has fallen to a 52-week low of $0.41. The 50-Day Moving Average of the stock is -13.61%, while the 200-Day Moving Average is calculated to be 15.71%.
Shares Statistics:
For the past three months, NKTR has traded an average of 1.88M shares per day and 1036710 over the past ten days. A total of 191.38M shares are outstanding, with a floating share count of 178.72M. Insiders hold about 2.88% of the company’s shares, while institutions hold 55.47% stake in the company. Shares short for NKTR as of 1721001600 were 9724532 with a Short Ratio of 4.69, compared to 1718323200 on 4337667. Therefore, it implies a Short% of Shares Outstanding of 9724532 and a Short% of Float of 6.760000400000001.
